Boehringer Ingelheim Pharmaceuticals Inc. will pay $13.5 million to all 50 states, including $178,000 to Iowa, to resolve allegations the drugmaker engaged in off-label marketing and deceptive and misleading representations in its promotion of four prescription drugs. The state attorneys general allege the global drug manufacturer misrepresented the drugs Micardis, Aggrenox, Atrovent and Combivent. The settlement, through a consent judgment filed Wednesday in Polk County District Court, resolves a consumer fraud petition also filed Wednesday. The agreement requires BIPI to ensure that its marketing and promotional practices do not unlawfully promote these prescription drug products. The company agreed to limit product sampling of the four drugs to health care providers whose clinical practice is consistent with the product labeling, among other conditions. An operating unit of Boehringer Ingelheim’s animal health business is located at the Iowa State University Research Park in Ames.